If the average drug the FDA approves takes $1B and 10 years to gain FDA approval, how are we doing?
We are a year away from approval for the first of what I believe will be multiple indications and we are at approximately $200M and six years. Delays and FDA complications is the norm not the exception.
Has Leronlimab failed in ANY way? Regardless of whether it takes 8 months or 16 months to gain FDA approval it seems a lock that HIV Combo approval will be granted by the almighty.
That will pave the way for Mono approval, which has been the unattainable prize within the HIV space. Does anybody here think BP will wait until final approval of Mono before pouncing? With the ability to effectively screen CCR5 density coupled with the discovery of the optimal 525ml dosage, Mono approval is simply a matter of time. The data speaks for itself. Disruption of the HIV space is a forgone conclusion and BP knows it. They also know this is a small company with limited resources, so hence the lack of urgency from BP and our ridiculously low SP valuation.
Then we have the Oncology wild card. TNBC is going to determine just how broad our potential is. First patient will get injected when the variables have been locked down to insure accurate results. The importance of this first P2 to CYDY’s future is immeasurable. I for one am in favor of crossing all t’s and dotting all i’s to give us the best opportunity. I trust Pestell would not place his life’s work on the line without meticulously working through all potential variables.
This is a seven employee operation working around the clock with a very intelligent and savvy BOD. Everyone of these people are in it to win it. They refuse to give this company away and have us, the shareholders backs. This talk of Nader and even Pestell milking there $600k annual gravy train is such BS.
Has Nader been overly optimistic and misleading? Yes to a fault. Does he do this purposely? I think not or I would be out. I, like many have been frustrated much of the time with the manner in which Nader communicates and represents this company. However, I will tell you he’s all in working around the clock to deliver what we all want; the maximum ROI. If there is a suitable replacement the BOD will make the move. IMO the strategy is to instead provide more support for Nader by hiring expertise like Dr.Rae. I think we will see more expertise that replace Nader’s weaknesses. This is not a BOD with their head in the sand.
The money will be raised one way or another and that is the elephant in the room at this moment. IMO the deals are there but they have to meet the parameters that are equitable to the equity that will be forfeited. We can call it dilution, but in reality it is simply the investment necessary to get to the holy grail.
